Simon Cartmell

Biography

 Simon Cartmell is a 35 year life-sciences industry veteran. He has pharmaceutical, biotech and med-tech experience gained in commercial, product development, supply chain, strategic leadership and corporate executive roles. Simon is a serial entrepreneur in early stage healthcare businesses. As CEO of ApaTech Ltd, a QMUL spinout, he developed the company from start up to world leading orthobiologics company prior to its sale for $330m to Baxter International Inc in March 2010. Before joining ApaTech in 2004 Simon was a Main Board Director of FTSE 100 Celltech Group plc, serving as CEO, Celltech Pharmaceuticals, prior to which he served as COO of FTSE 250 Vanguard Medica (later Vernalis plc). The early part of his career was spent at Glaxo/Glaxo Wellcome plc in a series of senior UK and international sales, marketing, supply chain and strategic development leadership roles. He is currently part time CEO and Director of Calon Cardio-Technology Ltd, an Operating Partner at Imperial Innovations plc for whom he serves, in addition to his role as Executive Chairman of Ieso Digital Health Ltd, as the Chairman and a Non-Executive Director of Veryan Medical Ltd and Non-Executive Director of Stanmore Implants Worldwide Ltd. He also serves as a Non-Executive Director of Creo Medical Ltd and of ReNeuron plc. Previously he has served as Chairman of, or a Non-Executive Director on, several private and public company Boards and as a member of the Office of Life Sciences and Ministerial Medical Technology Strategy Group

Research Interest

BIOTECH,  PHARMA industry